Literature DB >> 9168461

The pharmacokinetics of water-in-oil-in-water-type multiple emulsion of a new tacrolimus formulation.

T Uno1, T Yamaguchi, X K Li, Y Suzuki, H Hashimoto, Y Harada, T Kimura, T Kazui.   

Abstract

We developed a water-in-oil-in-water-type (W/O/W)-type multiple emulsion of a new tacrolimus formulation. A potential approach to avoid the complications of systemic immunosuppression and simultaneously enhance immunosuppressive efficacy is to deliver immunosuppressive agents locally to the site of the target organs. The W/O/W emulsion is dispersed oil drops containing smaller water droplets that allow the delivery of drugs preferentially to the reticuloendothelial systems (RES). Since the liver and the spleen are primary components of the RES, and the brain and the kidney have a poor RES, we hypothesized that a W/O/W emulsion of tacrolimus would possess the pharmacokinetic benefits of local immunosuppression. We evaluated this hypothesis in a rat model. The tacrolimus levels of whole blood, the liver, spleen, brain, and kidney in rats given intravenous emulsions of tacrolimus (W/O/W group) were compared with a group administered tacrolimus alone (T group). There were no significant differences between the pharmacokinetic parameters of W/O/W group and T group based on whole blood data. However, the W/O/W group had significantly decreased tacrolimus levels in the brain and kidney, and significantly increased levels in the liver and spleen compared with the T group. These data suggest that the W/O/W emulsion is applicable as an intravenous drug carrier for local immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9168461     DOI: 10.1007/s11745-997-0069-1

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  19 in total

1.  High brain densities of the immunophilin FKBP colocalized with calcineurin.

Authors:  J P Steiner; T M Dawson; M Fotuhi; C E Glatt; A M Snowman; N Cohen; S H Snyder
Journal:  Nature       Date:  1992-08-13       Impact factor: 49.962

2.  Changes in renal function after liver transplantation under FK 506.

Authors:  J McCauley; J J Fung; S Todo; A Jain; P Deballi; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

3.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

Authors:  T Kino; H Hatanaka; S Miyata; N Inamura; M Nishiyama; T Yajima; T Goto; M Okuhara; M Kohsaka; H Aoki
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

4.  A highly sensitive method to assay FK-506 levels in plasma.

Authors:  K Tamura; M Kobayashi; K Hashimoto; K Kojima; K Nagase; K Iwasaki; T Kaizu; H Tanaka; M Niwa
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

5.  [Leukocytosis induced by BH-AC administration--allergic reaction to Casteo oil HCO-60. A case report].

Authors:  S Ohta; S Iwane; T Katsura; M Shimada; S Hayashi
Journal:  Rinsho Ketsueki       Date:  1985-04

6.  [Drug eruption by solution trioxyethylene hydrogenated castor oil (HCO-60) in vitamin K2 (author's transl)].

Authors:  S Okabe
Journal:  Nihon Hifuka Gakkai Zasshi       Date:  1981-06

7.  The increased efficacy and decreased nephrotoxicity of a cyclosporine liposome.

Authors:  C E Freise; T Liu; K Hong; R W Osorio; D Papahadjopoulos; L Ferrell; N L Ascher; J P Roberts
Journal:  Transplantation       Date:  1994-03-27       Impact factor: 4.939

8.  Local cyclosporine immunotherapy of heart transplants in rats enhances survival.

Authors:  S F Bolling; H Lin; T M Annesley; J A Boyd; K P Gallagher; R J Levy
Journal:  J Heart Lung Transplant       Date:  1991 Jul-Aug       Impact factor: 10.247

9.  The enhanced immunosuppressive efficacy of newly developed liposomal FK506 in canine liver transplantation.

Authors:  S Ko; Y Nakajima; H Kanehiro; M Horikawa; A Yoshimura; J Taki; Y Aomatsu; T Kin; K Yagura; H Nakano
Journal:  Transplantation       Date:  1995-05-27       Impact factor: 4.939

10.  Physicochemical, pharmacokinetic and pharmacodynamic evaluation of liposomal tacrolimus (FK 506) in rats.

Authors:  M J Lee; R M Straubinger; W J Jusko
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

View more
  4 in total

1.  Therapeutic effect of 0.1% Tacrolimus Eye Ointment in Allergic Ocular Diseases.

Authors:  Rakesh K Barot; Satish C Shitole; Nupur Bhagat; Deepak Patil; Pawan Sawant; Kalpita Patil
Journal:  J Clin Diagn Res       Date:  2016-06-01

Review 2.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Development and Characterization of a Tacrolimus/Hydroxypropyl-β-Cyclodextrin Eye Drop.

Authors:  Xurxo García-Otero; Victoria Díaz-Tomé; Rubén Varela-Fernández; Manuel Martín-Pastor; Miguel González-Barcia; José Blanco-Méndez; Cristina Mondelo-García; Maria A Bermudez; Francisco Gonzalez; Pablo Aguiar; Anxo Fernández-Ferreiro; Francisco J Otero-Espinar
Journal:  Pharmaceutics       Date:  2021-01-23       Impact factor: 6.321

4.  Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement.

Authors:  Atsuki Fukushima; Yuichi Ohashi; Nobuyuki Ebihara; Eiichi Uchio; Shigeki Okamoto; Naoki Kumagai; Jun Shoji; Etsuko Takamura; Yayoi Nakagawa; Kenichi Namba; Hiroshi Fujishima; Dai Miyazaki
Journal:  Br J Ophthalmol       Date:  2014-04-02       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.